FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Breast cancer survivors
Women under 45
Women over 45
Men with breast cancer
Metastatic breast cancer
Triple negative breast cancer
BRCA mutation carriers
Her2+ breast cancer
Special populations: women who have been prescribed antidepressants
Previous research found an association between depression and survival in breast cancer patients, but the reasons for this association are unclear. Researchers in this study found that women who had been previously prescribed antidepressants were less likely to receive breast cancer treatment that followed national guidelines than those who had not. Although the difference was small, it underscores the need for patients to discuss any history of depression with their health care providers. (1/24/17)
Whether women with a history of depression before their initial early-stage breast cancer diagnosis are more likely to have breast cancer treatment that does not follow national guidelines and also whether they have poorer survival compared to women without a history of depression.
To identify groups of patients who may not be getting standard of care treatment that improves their chances of surviving breast cancer.
This study suggests that women who had early-stage breast cancer diagnoses and previous treatment for depression were more likely have cancer treatments that did not adhere to national guidelines and also have worse overall survival. A serious limitation of the study is that it could not address why these treatments did not follow national guidelines. While more work needs to be done to understand why this may be occurring, all breast cancer patients should feel comfortable asking their health care providers about their treatments, so that they can understand the reasons for the treatment and any other available options. Oncologists recommend breast cancer treatment based on many different pieces of information, including cancer stage, subtype of breast cancer (e.g. triple-negative breast cancer, ER/PR-positive, HER2-positive, etc.), and sometimes the results of prognostic tests or testing for inherited mutations in BRCA or other genes that increase cancer risk. In the United States, the National Comprehensive Cancer Network publishes versions of the national breast cancer treatment guidelines to help patients understand the current standard of care treatments and facilitate shared decision making with their physicians.
This is an interesting study that generates ideas for further research, but it should not cause alarm for patients who face both depression and cancer. People who are being actively treated for depression at the time of a cancer diagnosis or who have a history of depression should let their oncologists and other health care providers know so that their physicians can provide appropriate care or referrals. Everyone should inform their health care provider of all medications and supplements they are taking.
The same article was also covered by Fox News.
Oncology Nurse Advisor
Previous studies found an association between depression and survival after breast cancer, with people who have a history of depression experiencing worse rates of survival than those who do not. Nis Suppli and colleagues from the Danish Cancer Society Research Center published work in the Journal of Clinical Oncology in January 2017 to try to understand this association.
Do women who have previously been prescribed antidepressants receive different breast cancer treatments than women who have not taken antidepressants?
This study included 45,325 women from Denmark who were diagnosed with early-stage breast cancer between April 1998 through December 2011: 6,068 (13%) of the women had previously used antidepressants. Women with a previous cancer diagnosis or other major psychiatric disorders were excluded. The study authors used national cancer treatment guidelines and clinical data from the Danish Breast Cancer Group. Information on which women had been prescribed antidepressants was retrieved from the Danish Psychiatric Central Research Register.
Because the researchers used existing data from registries and did not collect it themselves, they were unable to differentiate between women who had undiagnosed or untreated depression and those who had depression but only had psychotherapy without antidepressants. (The registry information was collected over a 13½-year period during which treatment for both breast cancer and depression has evolved.) Nor did researchers take into account lifestyle factors such as alcohol use, smoking, and access to care. Another problem was the use of antidepressant prescriptions as a measure of the women with depression—this number could include patients who didn’t necessarily have depression, as antidepressants are often prescribed to treat anxiety, pain and other conditions; the number may have also missed people with depression who chose to treat it with other methods. Finally, because of the study design, researchers were unable to understand why treatment for patients who had been prescribed antidepressants was less likely to follow recommended national guidelines. Several reasons are possible, including patient preference, health care providers not offering guideline-based treatments, patients may not have been compliant, or a combination of these and/or other reasons.
It is also important to note that this study was conducted in the Danish health care system and does not necessarily reflect what is happening in the United States.
This study suggests that early-stage breast cancer patients who were previously treated for depression are more likely to receive cancer treatment other than treatment that is recommended by national guidelines. This is an interesting study that generates ideas for further research, but it should not cause alarm for patients who face both depression and cancer. Breast cancer patients or survivors with depression or a history of depression should discuss any concerns with their health care providers.
Suppli NP, Johansen C, Kessing LV, et al. “Survival after early-stage breast cancer of women previously treated for depression: a nationwide Danish cohort study.” Journal of Clinical Oncology. Published online first on November 14, 2016.
Share your thoughts on this XRAYS article by taking our brief survey
FORCE Information: Breast Cancer Treatment
FORCE Information: Hereditary Cancer Treatment Options
Be Empowered Webinars: Newly Diagnosed with Breast Cancer: What You Need to Know